Nilotinib, Indian WHO-GMP supply of the second-generation BCR-ABL TKI for Philadelphia-positive CML, including imatinib-resistant disease.

Hard capsules in 50, 150 and 200 mg. The 150 mg capsule supports the 300 mg twice-daily dose used in newly diagnosed chronic-phase CML; the 200 mg capsule supports the 400 mg twice-daily dose used in imatinib-resistant or intolerant chronic-phase and accelerated-phase disease; the 50 mg capsule supports dose adjustment for toxicity or hepatic impairment. Pack formats: Alu-Alu blister and HDPE bottle (typically 28, 40 or 120 capsules) for institutional and tender supply, all from Indian WHO-GMP-certified facilities. Nilotinib is taken twice daily on an empty stomach, the capsules swallowed whole, with no food for 2 hours before and 1 hour after each dose.

No. M Care is a merchant exporter. We supply nilotinib from Indian WHO-GMP-certified manufacturers (the major Indian generic lines include Natco, Hetero, Dr Reddy's, BDR and others) and handle export, documentation, registration support, freight and pharmacovigilance set-up. We do not run a manufacturing plant ourselves. For a buyer that means we route each order to the right WHO-GMP line for the destination, including an EU-GMP-capable line where the destination requires it, and carry the regulatory and logistics paperwork including the QT and cardiovascular-monitoring annexes.

Generic nilotinib supply is emerging and broadening, and verified per market on every quote. The originator compound patent has expired or is expiring across major markets, the first generic nilotinib approvals have been granted including by the US FDA, and Indian generic supply is available. Generic lanes are opening across sub-Saharan Africa, the GCC, ASEAN and Latin America. Because nilotinib generic timing is more recent than imatinib or dasatinib, secondary polymorph, salt and formulation patents are more likely to be live in particular jurisdictions, so we run a careful per-destination verification on every enquiry and supply only where it is lawful, refusing to quote where a live patent or settlement window blocks supply. We do not supply into India.

Both nilotinib and dasatinib are second-generation BCR-ABL tyrosine kinase inhibitors active against most imatinib-resistant mutations except T315I, and the choice between them is driven by the patient's comorbidity profile and, where known, the specific kinase-domain mutation. Nilotinib's distinctive burdens are the QT-prolongation and sudden-death boxed warning, the strict empty-stomach dosing rule, and a cardiovascular and metabolic signal, namely peripheral arterial occlusive disease, ischaemic events, hyperglycaemia and dyslipidaemia, which makes it less attractive in patients with significant vascular or metabolic risk. Dasatinib's distinctive burden is pleural effusion and, less commonly, pulmonary arterial hypertension, which makes it less attractive in patients with cardiopulmonary disease. Certain mutations also respond better to one agent than the other. The prescribing haematologist makes the selection; our role is to supply whichever the programme specifies, with the matching monitoring documentation.

Nilotinib carries a boxed warning for QT-interval prolongation and sudden death: an ECG is taken at baseline, repeated at around day 7 and periodically, hypokalaemia and hypomagnesaemia are corrected before and during treatment, and co-administered QT-prolonging drugs and strong CYP3A4 inhibitors are avoided. It must be taken on an empty stomach, with no food for 2 hours before and 1 hour after each dose, because food substantially raises nilotinib exposure and the QT risk. The other priority signals are myelosuppression (count-driven dose modification); cardiovascular and vascular events including peripheral arterial occlusive disease, ischaemic heart disease and ischaemic cerebrovascular events; metabolic effects of hyperglycaemia and dyslipidaemia requiring glucose and lipid monitoring; hepatotoxicity; pancreatitis (lipase and amylase monitoring); and electrolyte disturbance. Nilotinib is active against most imatinib-resistant BCR-ABL mutations but not the T315I gatekeeper mutation. The destination-language SmPC carries the full table for the receiving haematology service and dispensing pharmacy.

Subject to a careful per-market patent and licence verification because its generic timing is recent, the lawful lanes are opening. Sub-Saharan African public-sector oncology (SAHPRA, NAFDAC, KEMSA and PPB, FDA Ghana, EFDA, TMDA, NDA). GCC haematology centres (NUPCO and SFDA, MoHAP / DHA / DoH, and the Kuwait, Qatar, Oman and Bahrain ministries) through licensed importers. ASEAN and South Asia (Philippines FDA, Vietnam DAV, Indonesia BPOM, Bangladesh DGDA, Sri Lanka NMRA) and Latin America (Brazil ANVISA, Mexico COFEPRIS). UK and EU supply runs through the generic channel where our WHO-GMP partner lines hold the relevant authorisation and the patent position is clear. We do not supply into India. Full coverage at markets.

Batch-specific Certificate of Analysis (HPLC nilotinib assay, related substances per Ph.Eur./USP, polymorph identity, dissolution profile, content uniformity, water content), Method of Analysis, bioequivalence study report against the Tasigna reference for new registrations, Certificate of Pharmaceutical Product (CoPP) from CDSCO India, WHO-GMP certificate, manufacturing licence, per-destination patent-verification note, Certificate of Origin, and a destination-language pack insert carrying the QT-prolongation and sudden-death boxed warning, the empty-stomach dosing instruction, the cardiovascular and peripheral-arterial-occlusive-disease caution, the metabolic-monitoring guidance, the molecular-monitoring framework and the T315I-resistance caveat. CTD Module 3 dossier available against an NDA, see dossier preparation.